Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target

Stock Track

11/07

Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.

Despite the price target cut, Chardan maintained its "Buy" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.

The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains "overweight," with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1126022241"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1126022241\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1126022241?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 23:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126022241","market":"sg","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target","media":"Stock Track","content":"<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.</p>\n\n<p>Despite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.</p>\n\n<p>The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-11-07 23:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.</p>\n\n<p>Despite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.</p>\n\n<p>The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1126022241","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126022241","pubTimestamp":1762527781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"股票追踪|Chardan下调目标价，Iovance Biotherapeutics暴跌6.32%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.\nDespite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.\nThe move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}